Myeloma CAR T-Cell Therapy: Choosing Between Abecma and Carvykti

Introduction: Two CAR-T Options, One Important Decision

A patient with relapsed or refractory multiple myeloma may hear from an oncologist that CAR T-cell therapy is now a realistic option. That news is often followed by a harder question: which CAR-T? Two products are FDA-approved for multiple myeloma, Abecma (idecabtagene vicleucel, or ide-cel) and Carvykti (ciltacabtagene autoleucel, or cilta-cel). They share a common target and a similar treatment process, but they differ in eligibility, response data, and side-effect profiles.

This article assumes the reader already understands the general CAR-T process, timeline, and side effects, which are covered in other resources on this site. The focus here is narrower: an independent, data-driven, plain-language comparison to help patients and caregivers understand why an oncologist might recommend one product over the other.

The stakes are significant. Multiple myeloma is the second most common blood cancer. The American Cancer Society estimates about 36,000 new U.S. cases and roughly 10,850 deaths in 2026. Five-year relative survival sits around 55 to 62% and continues to improve as novel immunotherapies become more widely used. CAR-T is no longer a last resort; it has become a standard-of-care option, which makes the choice between products more consequential than ever.

What Abecma and Carvykti Have in Common

Before examining the differences, it helps to understand how much these two therapies share.

• Same target: Both are BCMA-directed (B-cell maturation antigen) CAR T-cell therapies. Each engineers a patient’s own T cells to recognize BCMA, a protein found on myeloma cells, and attack those cells.
• Same general process: Both require leukapheresis to collect T cells, a manufacturing lead time, lymphodepleting chemotherapy, a single infusion, and a period of intensive monitoring.
• Same safety program: Both carry REMS (Risk Evaluation and Mitigation Strategy) requirements. Patients must stay within a 2-hour radius of the treatment center for at least 4 weeks and avoid driving for 8 weeks after infusion.
• Same hallmark toxicities: Both are associated with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
• Same guideline status: The NCCN’s 2026 guidelines (v4.2026/v5.2026) list CAR-T as a preferred, category 1 option in early relapse, after one to two prior lines of therapy.

Meet the Two Products: Abecma (ide-cel) and Carvykti (cilta-cel)

Feature	Abecma (ide-cel)	Carvykti (cilta-cel)
Manufacturer	Bristol Myers Squibb (with 2seventy bio)	Johnson & Johnson and Legend Biotech
Initial FDA approval	March 2021	February 2022
Target antigen	BCMA	BCMA
Current earliest eligibility	After 2+ prior lines	After 1 prior line (lenalidomide-refractory)

When both therapies received expanded earlier-line approvals, reflecting a broader shift of these treatments into earlier lines of myeloma care, they marked the 14th and 15th CAR-T approvals overall. Patient advocacy organization Blood Cancer United described the expansions as a “big step toward” long-term control of myeloma.

Who Qualifies: FDA Eligibility by Prior Lines of Therapy

In April 2024, the FDA expanded both approvals to earlier lines of treatment. The expansions were not identical, and that difference shapes many treatment decisions today.

• Carvykti is approved after just one prior line of therapy for patients who are refractory to lenalidomide (Revlimid).
• Abecma is approved after two or more prior lines, including exposure to a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-CD38 antibody.

This distinction has real practical consequences. A patient who relapses early, with only one line of treatment behind them, may qualify only for Carvykti. In those cases, the choice is effectively narrowed before efficacy or safety is ever weighed.

The path to these approvals was carefully scrutinized. During its review, an FDA advisory committee examined early-death signals in both pivotal trials (CARTITUDE-4 for Carvykti and KarMMa-3 for Abecma). In both studies, survival curves crossed early before a later benefit emerged. After weighing that evidence, the panel voted 11-0 in favor of expanded approval, underscoring that these were rigorously vetted decisions.

Comparing Efficacy: What the Trials and Real-World Data Show

Efficacy comparisons come from two kinds of evidence, each with its own strengths. Randomized trials compare a CAR-T product against standard treatment under controlled conditions, but they do not compare Abecma and Carvykti directly. Real-world retrospective cohorts capture broader, more diverse patient populations treated outside of trials, though they lack the controls of randomization.

Randomized trial data: In the CARTITUDE-4 trial, Carvykti reduced the risk of myeloma progression or death by 59% compared with standard regimens (pomalidomide-bortezomib-dexamethasone or daratumumab-pomalidomide-dexamethasone). Abecma’s KarMMa-3 trial similarly demonstrated a benefit over standard regimens in its approved population, supporting its earlier-line approval.

Real-world data: A large retrospective cohort comparison of 386 Abecma patients and 255 Carvykti patients found:

• Overall response rate: 89% with Carvykti vs. 79% with Abecma
• Complete response rate: 70% with Carvykti vs. 47% with Abecma

These numbers suggest deeper responses with Carvykti on average. However, because the comparison was not randomized, differences between the patient groups may influence the results.

Comparing Safety: Toxicity Trade-Offs Between the Two Products

CRS and ICANS remain the defining toxicities of CAR-T therapy. Both are generally reversible when caught and treated promptly, which is a major reason REMS monitoring requirements exist.

The same retrospective cohort that showed stronger responses with Carvykti also found it associated with:

• Higher rates of severe CRS
• More delayed neurotoxicity (neurological effects that can appear weeks after infusion, a nuance specific to BCMA CAR-T)
• More infections
• A trend toward more secondary malignancies, an area under ongoing monitoring and research

Several other recognized toxicities apply to myeloma CAR-T more broadly:

• IEC-HS (immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome): a rare but serious hyperinflammatory condition
• ICAHT (prolonged cytopenias): low blood counts that can persist well beyond the infusion period
• Hypogammaglobulinemia: low antibody levels that typically require infection-prevention medication for at least 6 months after therapy

The core trade-off is clear. Carvykti offers potentially higher efficacy, while Abecma offers a different and, in some respects, milder side-effect profile. Neither product is risk-free, and the right balance depends on the individual patient.

Why Carvykti Has Become the Market Favorite, and Why That’s Not the Whole Story

Among U.S. centers offering both products, Carvykti holds roughly 80% of late-line market share, driven largely by its perceived superior efficacy.

Patients should interpret this figure with care. Market share reflects aggregate prescribing trends across thousands of patients, not a guarantee that one product is the best choice for every individual. A frail patient, someone with specific prior treatment exposures, or someone with particular health concerns may be better served by the alternative.

Ultimately, eligibility criteria, personal health history, disease characteristics, and prior treatment exposures drive the decision far more than market trends do.

Factors Your Care Team Weighs When Choosing Between Abecma and Carvykti

Oncologists typically consider several factors together:

1. Prior lines of therapy and drug refractoriness. The number of treatments a patient has received, and whether the disease is lenalidomide-refractory, determines which product is even an option.
2. Disease aggressiveness. When rapid, deep disease control is needed, the stronger response data for Carvykti may carry more weight.
3. Baseline health and frailty. Patients who may struggle to tolerate severe CRS, delayed neurotoxicity, or infections may be steered toward a product with a gentler expected profile.
4. Prior BCMA-targeted bispecific antibody exposure. Research shows that prior BCMA bispecific use can reduce the effectiveness of a later BCMA CAR-T. In CARTITUDE-2 Cohort C, bispecific-pretreated patients had only a 57% overall response rate and a 5-month median progression-free survival.
5. Center experience and logistics. Treatment center familiarity with each product, manufacturing slot availability, and scheduling can all influence the recommendation.

Patients and caregivers are encouraged to ask their oncology team directly: Which product do I qualify for, and why is this one being recommended for me?

Beyond Abecma vs Carvykti: Related Decisions Patients May Face

For some patients, the larger question is whether to pursue CAR-T at all or choose a bispecific antibody, such as teclistamab, elranatamab, talquetamab, or linvoseltamab.

Meta-analyses comparing the two approaches in relapsed or refractory myeloma show that CAR-T achieves higher complete response rates (54% vs. 31 to 35%) and higher overall response rates. That benefit comes with higher rates of severe CRS (7% vs. about 1%) and more hematologic toxicity.

The practical trade-off is straightforward:

• Bispecifics are “off-the-shelf” and can begin right away, but they typically require ongoing or indefinite dosing.
• CAR-T requires manufacturing lead time, but it is delivered as a single infusion.

Because prior bispecific use may blunt CAR-T efficacy, treatment sequencing deserves a deliberate conversation with the care team, especially if a bispecific has already been used or is being planned.

What’s on the Horizon: The Expanding CAR-T Pipeline

The CAR-T landscape for myeloma is evolving quickly:

• GPRC5D-directed CAR-T: Arlocabtagene autoleucel showed an 87% overall response rate and a 53% complete response rate in heavily pretreated patients, including those with prior BCMA exposure.
• Dual-target constructs: Therapies such as AZD0120, which targets both BCMA and GPRC5D, are advancing through Phase 2/3 testing.
• Next-generation BCMA CAR-T: Anito-cel showed a 61% overall response rate with 35% complete response or better in BCMA-naive patients in 2026 data, along with a notably shorter manufacturing turnaround of about 18 days.
• Smoldering myeloma: Early research is exploring CAR-T in high-risk smoldering myeloma, a pre-active stage of disease, as a potential early-intervention strategy distinct from current relapsed/refractory use.

Today’s choice between Abecma and Carvykti may soon expand to include additional FDA-approved options.

Practical Considerations Before Committing to Either Therapy

Regardless of which product is chosen, CAR-T demands significant time and planning:

• Time commitment: Leukapheresis takes 3 to 5 hours, followed by a manufacturing wait of several weeks, lymphodepleting chemotherapy, infusion, and extended monitoring.
• REMS restrictions: Patients must remain within a 2-hour radius of the treatment center for at least 4 weeks and avoid driving for 8 weeks.
• Financial and logistical burden: Costs are substantial and heavily front-loaded in the first weeks after infusion, with adverse-event management being a major driver of non-acquisition costs. Patients should ask about financial counseling and support resources through the treatment center’s care team.
• Caregiver planning: Caregivers should prepare for extended time away from work and home and arrange local lodging if the treatment center is not nearby.

Conclusion: Making an Informed, Personalized Choice

The core distinctions are clear. Carvykti offers stronger response data and eligibility after just one prior line of therapy for lenalidomide-refractory patients. Abecma remains an important option for patients with two or more prior lines and offers a somewhat different, in some respects milder, toxicity profile.

This is not a one-size-fits-all decision. Eligibility, disease biology, prior treatments, and personal health factors all shape the recommendation. The purpose of this comparison is to prepare patients and caregivers for a more informed, confident conversation with their oncology team, not to replace it. With new products, pipeline therapies, and expanding indications arriving steadily, staying engaged with up-to-date, trustworthy information has never mattered more.

Talk to Your Care Team About the Right CAR-T Option

Patients and caregivers can bring specific questions from this article to their next oncology appointment, such as:

• How many prior lines of therapy have I had, and am I lenalidomide-refractory?
• Have I been exposed to a BCMA-targeted bispecific antibody, and how does that affect my options?
• Which CAR-T product am I eligible for, and why is one being recommended over the other?
• What side effects should my caregiver and I prepare for with this specific product?

For deeper preparation, readers can explore related resources on this site covering the CAR-T process, timeline, and side-effect management. Before making a final decision, patients should seek personalized guidance from a certified CAR-T treatment center, where specialists can evaluate their full medical picture and help them choose the path that fits best.